Brello Health

Brello Health is a direct-to-consumer longevity health brand founded in 2023. It connects women with qualified healthcare providers for compounded GLP-1 wellness medications, specifically Tirzepatide and Semaglutide, prescribed through telehealth and delivered to members' doors. The company states an aim to remove traditional barriers of cost and complexity in healthcare, operating with transparent pricing, science-backed treatments and expert-led guidance for longevity medicine and weight management.

The company's work spans several technical domains: a digital health platform, telehealth, personalised coaching and progress tracking, AI-powered motivation, and compounded GLP-1 medications. Its consumer-facing verticals include women's health, longevity medicine, weight management, compounding pharmacy and wellness.

Brello Health's digital wellness platform, Brello Rise, gives members progress tracking, personalised coaching, AI-powered motivation and access to a community of more than 80,000 active members. The platform is intended to complement medical treatment with education and sustainable habit-building, combining medical expertise with ongoing human support.

Internally, the company describes itself as mission-driven, prioritising accessibility, transparency and genuine human support in how women access longevity medicine and weight management.